Hoth Therapeutics (NASDAQ:HOTH) Earns “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research note published on Monday morning,Benzinga reports. The brokerage currently has a $5.00 target price on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Hoth Therapeutics in a research note on Thursday, January 23rd.

Hoth Therapeutics Trading Down 2.9 %

NASDAQ HOTH opened at $1.00 on Monday. Hoth Therapeutics has a 12 month low of $0.58 and a 12 month high of $3.80. The stock has a market cap of $6.90 million, a PE ratio of -0.76 and a beta of 0.84. The stock’s 50 day moving average is $1.12 and its 200 day moving average is $1.01.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. On average, analysts forecast that Hoth Therapeutics will post -1.36 EPS for the current fiscal year.

Institutional Trading of Hoth Therapeutics

An institutional investor recently raised its position in Hoth Therapeutics stock. Geode Capital Management LLC boosted its position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 95,946 shares of the company’s stock after purchasing an additional 13,038 shares during the period. Geode Capital Management LLC owned about 1.39% of Hoth Therapeutics worth $72,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.